Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
| Autor: | Grinshpun, A., Ren, S., Graham, N., DeMeo, M.K., Wrabel, E., Carter, J., Tayob, N., Pereslete, A., Hamilton, E., Juric, D., Mayer, E.L., Tolaney, S.M., Krop, I.E., Metzger, O. |
|---|---|
| Zdroj: | In ESMO Open June 2024 9(6) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|